Publication:
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries

Simple item page
dc.contributor.authorCadena, Elsa de la
dc.contributor.authorMojica, María F.
dc.contributor.authorRíos, Rafael
dc.contributor.authorGarcía-Betancur, Juan Carlos
dc.contributor.authorDíaz, Lorena
dc.contributor.authorReyes, Jinnethe
dc.contributor.authorHernández-Gómez, Cristhian
dc.contributor.authorRadice, Marcela
dc.contributor.authorGales, Ana C.
dc.contributor.authorCastañeda Méndez, Paulo
dc.contributor.authorMunita, José
dc.contributor.authorPallares, Cristian José
dc.contributor.authorMartínez Solís, José Rodrigo Waldemar
dc.contributor.authorVillegas, María Virginia
dc.date.accessioned2023-07-07T21:51:10Z
dc.date.available2023-07-07T21:51:10Z
dc.date.issued2022
dc.description.abstractObjectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect bla KPC, bla NDM-1, bla VIM, and bla IMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated bla PDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.
dc.description.versionVersión publicada
dc.identifier.citationMojica MF, De La Cadena E, Ríos R, García-Betancur JC, Díaz L, Reyes J, Hernández-Gómez C, Radice M, Gales AC, Castañeda Méndez P, Munita JM, Pallares CJ, Martínez JRW, Villegas MV. Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries. Front Microbiol. 2022 Oct 24;13:1035609. doi: 10.3389/fmicb.2022.1035609.
dc.identifier.doihttps://doi.org/10.3389/fmicb.2022.1035609
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7673
dc.language.isoen
dc.subjectLatin America
dc.subjectPseudomonas aeruginosa
dc.subjectAntibiotic resistance
dc.subjectCeftolozane/tazobactam
dc.subjectMolecular mechanism
dc.titleMolecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceFrontiers in Microbiology
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fmicb-13-1035609 (1).pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services